Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

@article{Lepont2008PointMI,
  title={Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.},
  author={Pierig Lepont and John T. Stickney and Lauren A Foster and Jin-jun Meng and Robert F. Hennigan and Wallace Ip},
  journal={Mutation research},
  year={2008},
  volume={637 1-2},
  pages={
          142-51
        }
}

Figures and Tables from this paper

A novel alternative splicing isoform of NF2 identified in human Schwann cells.
TLDR
Although HSCs have an undetectable level of WT isoform of the NF2 protein merlin, they are not merlin-null, since they express the principle AS isoform, which has no suppressive effect on cell growth.
Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
TLDR
An untransformed merlin-deficient human Schwann cell line is established for use in drug discovery studies for NF2-associated schwannomas and their application in high-throughput screening of chemical libraries to identify compounds that decrease their viability.
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
TLDR
It is proposed that Gleevec should be evaluated in human schwannomas with shown progressive growth, and antitumorigenic effects were correlated to inhibition of PDGFR-alpha, PDG FR-beta, and c-kit activation/phosphorylation and major downstream signaling pathways.
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
TLDR
It is suggested that therapy with nilotinib or combinational therapy that  simultaneously inhibits PDGFR and the downstream Raf/MEK1/2/ERK1-2 pathway could represent an effective treatment for schwannomas and other merlin-deficient tumors.
KANK1 inhibits cell growth by inducing apoptosis though regulating CXXC5 in human malignant peripheral nerve sheath tumors
TLDR
It is reported that restoration of KANK1 in human MPNST cells inhibits cell growth both in human cell culture and xenograft mice by increasing apoptosis, and suggests that Kank1 may function as a tumor suppressor in humanMPNSTs, and thus it may be useful for targeted therapy.
Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways
TLDR
The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth and the regulation of merlin byCurcumin in both NF2 cells and neuroblastoma (non-NF2) cells provides a rationale for combining curcuming and KNK437 in the treatment of NF2.
Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.
TLDR
Apoptosis-associated speck-like protein (ASC) is identified as a putative schwannoma tumor suppressor with high potential clinical utility for schWannoma gene therapy and generated a vector that treatsSchwannomas via a novel mechanism that does not overlap with current treatments.
Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.
TLDR
PAK inhibitors induce cell death in schwannoma and meningioma cells, at least in part, by mitotic catastrophe.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells
TLDR
Results show that merlin isoform 1 is sufficient to restore normal actin organization in NF2-deficient human tumor cells, demonstrating a key role for merlin in the NF2 phenotype.
Exon scanning for mutation of the NF2 gene in schwannomas.
TLDR
Of a maximum of 60 alleles scanned, 32 showed mutations affecting expression of the merlin protein that are predicted to lead to a truncated protein due to frameshift, creation of a stop codon, or interference with normal splicing, while two are missense mutations.
Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
TLDR
Findings in primary schwannoma cells from NF2 patients strongly support the hypothesis of merlin acting as a tumour suppressor and may help in understanding development of humanschwannomas in NF2.
Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus
TLDR
The mutational skip of exon 15 and the expression of a protein with the COOH-terminus of isoform III correlates with the exceptionally mild NF2, and suggests tumor suppressor activity forisoform III.
The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts.
Neurofibromatosis type 2 (NF2) is an autosomal dominantly-inherited disorder predisposing affected individuals to tumors of multiple cell types in the central nervous system, including meningiomas. A
Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.
TLDR
To the authors' knowledge, this is the first attempt to establish permanent cell lines from human NF2 patients and this Schwann tumor-derived cell line may provide a useful model system for the study of familial NF2 tumor pathogenesis, for elucidating NF2 functions and for testing new gene-based therapeutic approaches.
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.
TLDR
It is reported that in contrast to the narrow spectrum of benign tumors in human NF2 patients, Nf2 heterozygous mice develop a variety of malignant tumors.
The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation.
TLDR
Mosaic studies demonstrate that merlin function is not required cell autonomously in mesoderm, and support the proposition that merlins function is essential for the development of extraembryonic structures during early mouse development.
Mutant Products of the NF2 Tumor Suppressor Gene Are Degraded by the Ubiquitin-Proteasome Pathway*
TLDR
Results suggest that degradation of mutant Sch mediated by the ubiquitin-proteasome pathway is a physiopathological pathway contributing to the loss of Sch function in NF2 patients.
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
TLDR
The tumor suppressor function of Nf2 was concealed in hemizygous N f2 mice because of insufficient rate of second allele inactivation in this cell compartment, and the finding of this conserved function documents the relevance of the present approach to model the human disease.
...
...